MedPath

Moderna

Moderna logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2010-01-01
Employees
5.6K
Market Cap
$30.3B
Website
http://www.modernatx.com
Introduction

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Phase 1
Recruiting
Conditions
Methylmalonic Acidemia
Interventions
First Posted Date
2021-05-24
Last Posted Date
2025-03-25
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
63
Registration Number
NCT04899310
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States

🇺🇸

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 14 locations

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Phase 3
Completed
Conditions
SARS-CoV-2
Interventions
Biological: mRNA-1273
First Posted Date
2021-04-26
Last Posted Date
2024-06-18
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
234
Registration Number
NCT04860297
Locations
🇺🇸

Aventiv Research Inc, Mesa, Arizona, United States

🇺🇸

California Institute of Renal Research, San Diego, California, United States

🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

and more 12 locations

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Phase 1
Completed
Conditions
SARS-CoV-2
Interventions
Biological: mRNA-1283
Biological: mRNA-1273
Biological: Placebo
First Posted Date
2021-03-24
Last Posted Date
2023-08-01
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
104
Registration Number
NCT04813796
Locations
🇺🇸

Synexus Clinical Research US Phoenix Southeast, Inc., Chandler, Arizona, United States

🇺🇸

Optimal Research San Diego, LLC, San Diego, California, United States

🇺🇸

Optimal Research Melbourne, LLC, Melbourne, Florida, United States

and more 2 locations

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Phase 2
Completed
Conditions
SARS-CoV-2
Interventions
First Posted Date
2021-03-15
Last Posted Date
2025-06-13
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
11942
Registration Number
NCT04796896
Locations
🇺🇸

Children's of Alabama, Birmingham, Alabama, United States

🇺🇸

MedPharmics, LLC, Albuquerque, New Mexico, United States

🇺🇸

Emmaus Research Center Inc, Anaheim, California, United States

and more 87 locations

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Phase 2
Completed
Conditions
SARS-CoV-2
Interventions
First Posted Date
2020-12-02
Last Posted Date
2024-10-22
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
4331
Registration Number
NCT04649151
Locations
🇺🇸

Velocity Clinical Research - Banning, Banning, California, United States

🇺🇸

Paradigm Clinical Research, La Mesa, California, United States

🇺🇸

Altus Research - Hunt - PPDS, Lake Worth, Florida, United States

and more 49 locations

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Phase 1
Completed
Conditions
Respiratory Syncytial Virus
Interventions
Biological: mRNA-1345
Drug: Placebo
First Posted Date
2020-08-27
Last Posted Date
2024-08-07
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
651
Registration Number
NCT04528719
Locations
🇺🇸

Paradigm Clinical Research Institute Inc - ClinEdge - PPDS, La Mesa, California, United States

🇺🇸

Mills Clinical Research, West Hollywood, California, United States

🇺🇸

Accel Research Site - Angel Kids Pediatrics - ERN - PPDS, DeLand, Florida, United States

and more 28 locations

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Phase 3
Completed
Conditions
SARS-CoV-2
Interventions
Biological: mRNA-1273
Biological: Placebo
First Posted Date
2020-07-14
Last Posted Date
2024-03-21
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
30415
Registration Number
NCT04470427
Locations
🇺🇸

Ascension St. Vincent Birmingham, Birmingham, Alabama, United States

🇺🇸

Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States

🇺🇸

Hope Research Institute, Phoenix, Arizona, United States

and more 87 locations

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Phase 2
Completed
Conditions
SARS-CoV-2
Interventions
Biological: mRNA-1273.351
Biological: Placebo
First Posted Date
2020-05-28
Last Posted Date
2022-12-30
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
660
Registration Number
NCT04405076
Locations
🇺🇸

Meridian Clinical Research, Dakota Dunes, South Dakota, United States

🇺🇸

Alliance for Multispecialty Research, Kansas City, Missouri, United States

🇺🇸

Trial Management Associates, Wilmington, North Carolina, United States

and more 1 locations

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Phase 2
Completed
Conditions
Cytomegalovirus Infection
Interventions
Other: Placebo
Biological: mRNA-1647
First Posted Date
2020-01-18
Last Posted Date
2024-01-03
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
315
Registration Number
NCT04232280
Locations
🇺🇸

Benchmark Research, Sacramento, California, United States

🇺🇸

Optimal Research, Peoria, Illinois, United States

🇺🇸

Johnson County Clin-Trials, Lenexa, Kansas, United States

and more 6 locations

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Phase 1
Recruiting
Conditions
Propionic Acidemia
Interventions
First Posted Date
2019-11-12
Last Posted Date
2025-03-28
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
68
Registration Number
NCT04159103
Locations
🇯🇵

Fujita Health University Hospital, Toyoake-shi, Aichi, Japan

🇯🇵

Tohoku University Hospital, Sendai-Shi, Miyagi, Japan

🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath